AASLD: Rapid Response for Once-Daily Protease Inhibitor (CME/CE)

BOSTON (MedPage Today) — The vast majority of patients with hepatitis C virus infection respond rapidly to a novel, once-daily protease inhibitor that may also mitigate the effects of a mutation predicting worse response to standard combination therapy, researchers reported here.

Post a Comment

Comments are closed.